These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31409568)

  • 1. Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin.
    Celik H; Wakim P; Pritchard WF; Castro M; Leonard S; Karanian JW; Dewhirst MW; Lencioni R; Wood BJ
    J Vasc Interv Radiol; 2019 Dec; 30(12):1908-1914. PubMed ID: 31409568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
    Tak WY; Lin SM; Wang Y; Zheng J; Vecchione A; Park SY; Chen MH; Wong S; Xu R; Peng CY; Chiou YY; Huang GT; Cai J; Abdullah BJJ; Lee JS; Lee JY; Choi JY; Gopez-Cervantes J; Sherman M; Finn RS; Omata M; O'Neal M; Makris L; Borys N; Poon R; Lencioni R
    Clin Cancer Res; 2018 Jan; 24(1):73-83. PubMed ID: 29018051
    [No Abstract]   [Full Text] [Related]  

  • 3. Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center.
    Yang W; Lee JC; Chen MH; Zhang ZY; Bai XM; Yin SS; Cao K; Wang S; Wu W; Yan K
    J Cancer Res Ther; 2019; 15(4):773-783. PubMed ID: 31436231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
    Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
    J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors.
    Hong CW; Chow L; Turkbey EB; Lencioni R; Libutti SK; Wood BJ
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):409-16. PubMed ID: 26228246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer.
    Poon RT; Borys N
    Future Oncol; 2011 Aug; 7(8):937-45. PubMed ID: 21823888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis.
    Chu HH; Kim JH; Yoon HK; Ko HK; Gwon DI; Kim PN; Sung KB; Ko GY; Kim SY; Park SH
    J Vasc Interv Radiol; 2019 Oct; 30(10):1533-1543. PubMed ID: 31471190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.
    Poon RT; Borys N
    Expert Opin Pharmacother; 2009 Feb; 10(2):333-43. PubMed ID: 19236203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional Chemoembolization Plus Radiofrequency Ablation versus Surgical Resection for Single, Medium-Sized Hepatocellular Carcinoma: Propensity-Score Matching Analysis.
    Lee HJ; Kim JW; Hur YH; Cho SB; Lee BC; Lee BK; Hwang EC; Cho YS; Seon HJ
    J Vasc Interv Radiol; 2019 Mar; 30(3):284-292.e1. PubMed ID: 30819467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma: Does the Degree of Ethiodized Oil Accumulation within the Tumor Affect the Therapeutic Efficacy?
    Lee JE; Kim JW; Kim HO; Lee BC; Hur YH; Cho SB; Cho YS; Seon HJ; Kim D
    J Vasc Interv Radiol; 2019 Mar; 30(3):370-379.e4. PubMed ID: 30819479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
    Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
    Wood BJ; Poon RT; Locklin JK; Dreher MR; Ng KK; Eugeni M; Seidel G; Dromi S; Neeman Z; Kolf M; Black CD; Prabhakar R; Libutti SK
    J Vasc Interv Radiol; 2012 Feb; 23(2):248-55.e7. PubMed ID: 22178041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.
    Soundararajan A; Dodd GD; Bao A; Phillips WT; McManus LM; Prihoda TJ; Goins BA
    Radiology; 2011 Dec; 261(3):813-23. PubMed ID: 22025735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study.
    Lencioni R; Crocetti L; Petruzzi P; Vignali C; Bozzi E; Della Pina C; Bargellini I; Cioni D; Oliveri F; De Simone P; Bartolozzi C; Brunetto M; Filipponi F
    J Hepatol; 2008 Aug; 49(2):217-22. PubMed ID: 18486261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.
    Lencioni R; Cioni D
    Hepat Oncol; 2016 Aug; 3(3):193-200. PubMed ID: 30191041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant liposomal doxorubicin markedly affects radiofrequency ablation-induced effects on periablational microvasculature.
    Moussa M; Goldberg SN; Tasawwar B; Sawant RR; Levchenko T; Kumar G; Torchilin VP; Ahmed M
    J Vasc Interv Radiol; 2013 Jul; 24(7):1021-33. PubMed ID: 23664809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center.
    Potretzke TA; Ziemlewicz TJ; Hinshaw JL; Lubner MG; Wells SA; Brace CL; Agarwal P; Lee FT
    J Vasc Interv Radiol; 2016 May; 27(5):631-8. PubMed ID: 27017124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.